🚀 VC round data is live in beta, check it out!
PharmaLundensis Valuation Multiples
Discover revenue and EBITDA valuation multiples for PharmaLundensis and similar public comparables like GeNeuro, Cannovum Cannabis, Respiratorius, Stayble Therapeutics and more.
PharmaLundensis Overview
About PharmaLundensis
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.
Founded
2006
HQ
Employees
1
Website
Sectors
Financials (FY)
EV
$2M
PharmaLundensis Financials
PharmaLundensis reported last fiscal year revenue of — and negative EBITDA of ($630K).
In the same fiscal year, PharmaLundensis generated ($630K) in EBITDA losses and had net loss of ($776K).
PharmaLundensis P&L
In the most recent fiscal year, PharmaLundensis reported revenue of — and EBITDA of ($630K).
PharmaLundensis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($630K) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($776K) | XXX | XXX | XXX |
| Net Debt | — | — | $388K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PharmaLundensis Stock Performance
PharmaLundensis has current market cap of $1M, and enterprise value of $2M.
Market Cap Evolution
PharmaLundensis' stock price is $0.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2M | $1M | 0.3% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPharmaLundensis Valuation Multiples
PharmaLundensis trades at (2.4x) EV/EBITDA.
PharmaLundensis Financial Valuation Multiples
As of April 19, 2026, PharmaLundensis has market cap of $1M and EV of $2M.
Equity research analysts estimate PharmaLundensis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PharmaLundensis has a P/E ratio of (1.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1M | XXX | $1M | XXX | XXX | XXX |
| EV (current) | $2M | XXX | $2M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (2.1x) | XXX | XXX | XXX |
| P/E | — | XXX | (1.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PharmaLundensis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PharmaLundensis Margins & Growth Rates
PharmaLundensis' revenue in the last fiscal year grew by —.
PharmaLundensis' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
PharmaLundensis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 164% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PharmaLundensis Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| PharmaLundensis | XXX | XXX | XXX | XXX | XXX | XXX |
| GeNeuro | XXX | XXX | XXX | XXX | XXX | XXX |
| Cannovum Cannabis | XXX | XXX | XXX | XXX | XXX | XXX |
| Respiratorius | XXX | XXX | XXX | XXX | XXX | XXX |
| Stayble Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Reboost Blockchain | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PharmaLundensis M&A Activity
PharmaLundensis acquired XXX companies to date.
Last acquisition by PharmaLundensis was on XXXXXXXX, XXXXX. PharmaLundensis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PharmaLundensis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPharmaLundensis Investment Activity
PharmaLundensis invested in XXX companies to date.
PharmaLundensis made its latest investment on XXXXXXXX, XXXXX. PharmaLundensis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PharmaLundensis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PharmaLundensis
| When was PharmaLundensis founded? | PharmaLundensis was founded in 2006. |
| Where is PharmaLundensis headquartered? | PharmaLundensis is headquartered in Sweden. |
| How many employees does PharmaLundensis have? | As of today, PharmaLundensis has over 1 employees. |
| Is PharmaLundensis publicly listed? | Yes, PharmaLundensis is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of PharmaLundensis? | PharmaLundensis trades under PHAL ticker. |
| When did PharmaLundensis go public? | PharmaLundensis went public in 2010. |
| Who are competitors of PharmaLundensis? | PharmaLundensis main competitors are GeNeuro, Cannovum Cannabis, Respiratorius, Stayble Therapeutics. |
| What is the current market cap of PharmaLundensis? | PharmaLundensis' current market cap is $1M. |
| Is PharmaLundensis profitable? | No, PharmaLundensis is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.